Nyxoah S.A.
General ticker "NYXH" information:
- Sector: Health Care
- Industry: Health Care Equipment & Supplies
- Capitalization: $283.8M (TTM average)
Nyxoah S.A. does not follow the US Stock Market performance with the rate: -17.7%.
Estimated limits based on current volatility of 2.4%: low 4.70$, high 4.93$
Factors to consider:
- Total employees count: 106 as of 2021
- Price in estimated range
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [3.61$, 9.89$]
- 2025-12-31 to 2026-12-31 estimated range: [3.00$, 8.31$]
Financial Metrics affecting the NYXH estimates:
- Negative: with PPE of -4.1 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -19.58 <= 0.33
- Positive: -14.38 < Investing cash flow per share per price, % of -6.49
- Negative: negative Net income
- Positive: Shareholder equity ratio, % of 71.50 > 63.39
Short-term NYXH quotes
Long-term NYXH plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | €3.08MM | €4.35MM | €4.52MM |
| Operating Expenses | €35.58MM | €49.45MM | €63.33MM |
| Operating Income | €-32.50MM | €-45.10MM | €-58.81MM |
| Non-Operating Income | €2.44MM | €0.45MM | €2.38MM |
| Interest Expense | €0.24MM | €1.21MM | €1.90MM |
| R&D Expense | €15.86MM | €27.66MM | €34.33MM |
| Income(Loss) | €-30.06MM | €-44.66MM | €-56.43MM |
| Profit(Loss)* | €-31.23MM | €-43.21MM | €-59.24MM |
| Stockholders Equity | €120.32MM | €98.11MM | €113.25MM |
| Inventory | €0.88MM | €3.31MM | €4.72MM |
| Assets | €146.07MM | €124.16MM | €158.41MM |
| Operating Cash Flow | €-28.76MM | €-44.78MM | €-49.23MM |
| Capital expenditure | €16.35MM | €10.96MM | €6.07MM |
| Investing Cash Flow | €-89.95MM | €32.01MM | €-16.32MM |
| Financing Cash Flow | €-0.98MM | €16.86MM | €77.44MM |
| Earnings Per Share** | €-1.21 | €-1.55 | €-1.81 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.